Author: Fiona Craig

Creo Medical Group (LSE:CREO) announced a 40% rise in core technology revenues for the first half of 2025, meeting management’s expectations and setting the stage for ongoing expansion. The company has improved operational efficiency, cutting costs and losses while bolstering its cash reserves. Recent regulatory approvals and new strategic partnerships, particularly in the US, are expected to accelerate the uptake of its advanced energy surgical products.

Strategic moves such as selling a 51% stake in Creo Medical Europe and divesting parts of its Chepstow facility aim to strengthen cash flow and simplify operations. The company remains confident in its growth trajectory and is dedicated to improving treatment options for patients with pre-cancerous and cancerous conditions globally.

Despite solid corporate developments, Creo Medical’s outlook is tempered by ongoing financial challenges and valuation concerns. Technical indicators currently show a neutral to slightly bearish trend, which impacts the overall assessment.

About Creo Medical

Creo Medical specializes in developing minimally invasive electrosurgical devices, focusing on enhancing patient care through innovative energy-based endoscopy. Its flagship CROMA technology, powered by Kamaptive, combines multiple energy modalities to enable precise and safer surgical interventions, offering less invasive and more cost-effective solutions in surgery and endoscopy.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Kromek Group plc (LSE:KMK) has secured a notable £1.7 million contract as part of the UK Government’s Radiological Nuclear Detection Framework, marking a key achievement in the company’s growth trajectory. This agreement includes the provision of the D3S-ID wearable radiation detectors and associated services, which are expected to contribute to increased revenues within Kromek’s CBRN Detection division.

The award highlights Kromek’s established position and expansion potential in the radiological and nuclear detection market, reinforcing its role in supporting national security efforts.

While the company benefits from positive corporate developments and encouraging technical signals, ongoing financial and profitability challenges continue to influence its overall outlook.

About Kromek Group plc

Kromek Group plc is a leading innovator in radiation and bio-detection technologies. Headquartered in County Durham, UK, with operations extending to the US, the company designs and manufactures advanced detector components for medical, industrial, and security applications. Kromek specializes in nuclear radiation detection solutions for homeland defense and security markets, and is actively developing bio-security products aimed at detecting airborne pathogens.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Primary Health Properties PLC (LSE:PHP) has reported the latest acceptance figures for its ongoing takeover bid for Assura Plc. As of July 18, 2025, the company has secured valid acceptances representing around 1.18% of Assura’s outstanding ordinary shares. PHP is encouraging remaining Assura shareholders to respond to the revised offer by the deadline of August 12, 2025.

This acquisition aligns with PHP’s strategic objective to broaden its footprint within the healthcare real estate sector, potentially strengthening its market position and creating enhanced growth opportunities for investors.

Financially, Primary Health Properties maintains a solid foundation with a strong equity base and no debt, supporting operational resilience. Technical indicators point to positive momentum, though the relatively high price-to-earnings ratio suggests caution on valuation. The company’s acquisition strategy, including the potential merger with Assura, is expected to bolster its portfolio quality and income streams. Recent earnings calls highlight growth prospects driven by rising rental income and effective asset management, despite some operational headwinds.

About Primary Health Properties PLC

Primary Health Properties is a UK and Ireland-based real estate investment trust (REIT) focused on owning and managing modern, purpose-built healthcare facilities. Its portfolio primarily serves general practitioners, health service providers, and other healthcare professionals, aiming to support the delivery of high-quality primary care.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Red Rock Resources Plc (LSE:RRR) has provided a status update on its ongoing arbitration case in the Democratic Republic of Congo, where it is awaiting a Supreme Court ruling that could validate its claim for $4.503 million against a former joint venture partner. Meanwhile, the company is adjusting payment schedules related to its Australian assets and expects to receive royalty revenues from its gold projects in Colombia. In the Ivory Coast, Red Rock is actively reviewing offers for its gold portfolio, which may attract a premium valuation.

Facing financial pressures, the company is pursuing strategies to stabilize its position, including potential asset disposals and equity fundraising efforts, all while awaiting the outcome of the DRC legal proceedings.

Red Rock’s shares have experienced downward pressure amid ongoing profitability challenges and negative cash flow. Although technical signals hint at possible future improvements, the company’s valuation remains weak, with a negative price-to-earnings ratio and no dividend payouts. The legal case in the DRC and recent equity issues underscore both potential opportunities and risks ahead.

About Red Rock Resources

Red Rock Resources Plc is a natural resources exploration and development company focused on gold, base metals, battery metals, and hydrocarbons. Its operations are primarily based in Africa and Australia, targeting projects with growth and value potential.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Defence Holdings PLC (LSE:ALRT), formerly operating as Guild Esports PLC, has officially pivoted from the esports arena to the defence technology sector in a sweeping strategic overhaul. The company completed the sale of its esports division to DCB Sports LLC, shedding over £2 million in liabilities and securing £100,000 in cash, thereby significantly improving its financial standing.

This transformation marks the launch of a five-year strategic roadmap aimed at establishing Defence Holdings as a leading force in AI-powered defence and security technologies. Backed by a recent £3.45 million capital raise, the company is now focused on developing and acquiring cutting-edge solutions in areas such as autonomous systems, secure communications, advanced sensors, and AI-driven analytics.

About Defence Holdings PLC

Based in London, Defence Holdings PLC is a publicly listed defence technology company serving the UK and European markets. The firm specializes in high-performance, next-generation systems designed to deliver operational advantages across all domains—land, sea, air, space, and cyber. Through a focus on AI innovation and strategic asset development, Defence Holdings is aiming to reshape the landscape of modern defence capabilities.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Mosman Oil and Gas Limited (LSE:MSMN) has announced progress at its Sagebrush helium project in Colorado, where it holds an 82.5% working interest. The company has engaged independent consultancy Sproule Incorporated to conduct a formal assessment of helium resources, aimed at verifying and refining Mosman’s internal estimates. In addition, the company is preparing to undertake a 3D seismic survey and extended production testing of the Sagebrush-1 well, collecting vital data to support future exploration and commercialization strategies.

These initiatives mark an important phase in de-risking the project and advancing it toward potential commercial development. The work is expected to be funded using Mosman’s existing cash reserves, reflecting its strategic commitment to helium as a core focus.

While the company faces financial headwinds, including profitability concerns and a weak valuation profile, recent technical indicators and corporate developments suggest potential for incremental progress. A shift in strategic focus toward helium and a strengthened equity position may help lay the groundwork for longer-term gains.

About Mosman Oil and Gas Limited

Mosman Oil and Gas is a dual-focused exploration and development company with operations in the United States and Australia. The company is involved in the search for and development of helium, hydrogen, and traditional hydrocarbon resources. With an emphasis on assets offering both near-term cash flow and long-term growth potential, Mosman continues to reposition itself toward emerging energy markets, particularly the helium sector.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Verici Dx Plc (LSE:VRCI) has announced plans to raise a minimum of £5 million through a combination of new share placements, a direct subscription from a U.S. investor, and a retail offering. The capital raise is aimed at supporting the commercial rollout of the company’s cutting-edge kidney transplant diagnostic tools, positioning Verici for accelerated growth and greater market penetration in the organ transplant sector.

The funds will enable the company to expand the reach of its core products, including its flagship Tutivia™ test, which supports early detection of acute rejection in kidney transplant patients and is covered under Medicare. Despite facing ongoing profitability challenges and weak technical indicators, Verici’s strategic fundraising signals a push toward long-term value creation and broader clinical adoption.

About Verici Dx Plc

Verici Dx is a UK-based clinical diagnostics company specializing in advanced blood-based testing for the organ transplant market. Focused primarily on kidney transplants, the company’s product suite addresses critical gaps in post-transplant care. Its next-generation diagnostic tools aim to improve patient outcomes through early and precise detection of immune responses. With a growing footprint in the U.S. and innovative technologies backed by clinical validation, Verici is working to transform transplant monitoring and management.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Wise PLC (LSE:WISE) has unveiled plans for a corporate restructuring that would see the creation of Wise Holdco as a new parent company, alongside a proposed dual listing on a U.S. stock exchange in addition to its existing London listing. The move aims to improve the company’s visibility and access to capital, particularly in the strategically important U.S. market.

Although the proposal has drawn some pushback from a shareholder, Wise’s Board maintains strong support from the broader shareholder base and views the reorganization as a step aligned with the company’s long-term mission. The proposal features a dual-class share structure with a 10-year sunset clause, mirroring governance practices commonly found in the U.S. tech sector.

Wise continues to report solid financial performance and sustained growth, backed by robust operational metrics and strategic momentum. While technical indicators suggest potential short-term fluctuations, the company remains in a strong position, albeit with a moderate valuation and no current dividend offering.

About Wise PLC

Founded in 2011, Wise is a global financial technology company specializing in low-cost, cross-border money transfers and multi-currency account services. Through its Wise Account and Wise Business platforms, the company empowers individuals and enterprises to send, receive, and manage money across 40 currencies. In fiscal year 2025, Wise processed over $185 billion in transactions, saving customers an estimated $2.6 billion in fees. Widely regarded as one of the fastest-growing fintech firms globally, Wise continues to redefine the international payments space.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Portmeirion Group PLC (LSE:PMP) has reported a 2.8% rise in revenue on a constant currency basis for the first half of 2025, with growth reaching 10.8% when excluding the impact of its U.S. operations. The company continues to face headwinds from U.S. import tariffs, which have prompted a strategic realignment, including ramping up domestic manufacturing in the UK and reshaping its approach to the American market.

Despite these challenges, Portmeirion posted strong performances in South Korea and other international markets. Its Wax Lyrical brand also delivered solid results in the UK. Looking ahead, the company expects modest sales growth in the second half of the year, driven by ongoing momentum in its international divisions, though it remains cautious about U.S. market conditions.

Portmeirion’s financial outlook is tempered by ongoing volatility in cash flow and revenue, contributing to a subdued valuation. While insider share purchases offer a degree of confidence, technical indicators currently suggest negative momentum. The company is focusing on operational stability and international expansion to strengthen its long-term prospects.

About Portmeirion Group PLC

Portmeirion is a renowned British homeware company headquartered in Stoke-on-Trent, England. The group owns a portfolio of six iconic brands—Spode, Portmeirion, Royal Worcester, Pimpernel, Wax Lyrical, and Nambé. Serving global markets, the company has a strong presence in the UK, North America, and South Korea, offering products that blend heritage craftsmanship with modern design.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Assura plc (LSE:AGR) has announced solid financial results for the fiscal year ending March 31, 2025, underscored by a 17% rise in net rental income to £167.1 million and a boost in the value of its investment portfolio, which now stands at £3.1 billion. The healthcare-focused REIT executed a disciplined growth strategy, acquiring 14 independent hospitals and completing five key development projects during the year.

In parallel, Assura continued to advance its ESG agenda, achieving meaningful progress in net zero carbon developments and generating increased social value through its properties and initiatives. These accomplishments, coupled with active portfolio management and strong cash flows, have positioned the company to continue delivering shareholder returns through sustained growth and consistent dividend payouts.

Despite facing some profitability constraints due to recurring net losses, Assura’s robust asset base and focus on operational efficiency offer a promising outlook. Strategic actions and technical strength support growing investor confidence as the company continues to expand its role in the UK and Ireland’s healthcare infrastructure.

About Assura plc

Assura is a UK-based Real Estate Investment Trust (REIT) specializing in the development and ownership of healthcare properties. With a portfolio of over 600 medical buildings serving more than six million people, the company plays a key role in supporting primary care services across the UK and Ireland. Assura is listed on the FTSE 250 and the EPRA indices, and also maintains a secondary listing on the Johannesburg Stock Exchange. As the first FTSE 250 company to achieve B Corp certification, Assura places ESG principles at the core of its business model.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.